Beyond the Flu Shot: RQ Bio's $115M Bet on Season-Long Immunity

LONDON, UK – June 24, 2026 – In a move that signals a tectonic shift in the fight against seasonal influenza, UK-based RQ Bio has secured an oversubscribed USD 115 million Series A financing round. The substantial investment, led by Frazier Life Sciences, is not just another bet on biotech; it's a strategic deployment of capital aimed at fundamentally changing how we protect our most vulnerable populations from a persistent viral threat.

RQ Bio's mission is to move beyond the limitations of traditional vaccines with a single-administration antibody therapy designed to provide protection for an entire flu season. This funding catapults their lead candidate, RQB01, toward clinical trials and validates a new front in public health resilience.

A New Shield for the Vulnerable

For decades, the public health mantra has been the annual flu shot. While these vaccines are a cornerstone of infectious disease prevention, their effectiveness can be a coin toss, varying with each season's viral strains and, critically, the recipient's own immune system. For the elderly, the immunocompromised, and those with chronic health conditions, a flu vaccine may not trigger a strong enough response, leaving them dangerously exposed.

This is the critical unmet need RQ Bio aims to fill. Instead of prompting the body to create its own antibodies—a process that can be weak or inconsistent in vulnerable individuals—RQ Bio's approach delivers a potent dose of pre-made, laboratory-developed monoclonal antibodies. This 'passive immunity' provides an immediate and durable shield against the virus.

Their lead program, RQB01, is engineered to target highly conserved parts of the influenza virus, meaning it aims for sections of the virus that change little from season to season. This strategy is a direct attempt to overcome the 'antigenic drift' that forces vaccine manufacturers into an annual race to predict the next dominant strains. The goal is ambitious but clear: a single, reliable injection that protects a high-risk individual from September to spring.

The Strategic Capital Fueling Innovation

The syndicate of investors backing RQ Bio is as significant as the sum they raised. The round was led by Frazier Life Sciences and saw participation from a formidable group of new and existing investors, including EQT Life Sciences, Forbion, and Wellington Management, alongside founding investors like LifeArc and Oxford Science Enterprises.

This collection of top-tier life science investors signals deep confidence in both the science and the strategy. This is not speculative capital; it is a calculated investment in a platform with demonstrated potential. As Felice Verduyn - van Weegen, Partner at EQT Life Sciences, noted, "Influenza continues to pose a significant burden for high-risk populations, despite the availability of existing treatments. RQ Bio's single-administration approach to durable, season-long protection addresses a clear unmet need among the patients who remain most vulnerable."

EQT Life Sciences' commitment extends beyond the checkbook, promising to leverage its experience to help scale the organization and navigate the complex path of clinical development. This hands-on, strategic partnership is crucial for a company transitioning from a promising startup to a clinical-stage enterprise with the potential for global impact.

Proven Leadership for a High-Stakes Journey

To underscore its ambitions, RQ Bio has appointed Christian S. Schade as Executive Chairman. Schade is not just an experienced executive; he is a biotech leader with a multi-billion-dollar success story on his resume. As the former President and CEO of Halda Therapeutics, he orchestrated the company's USD 3.0 billion acquisition by Johnson & Johnson in 2025.

His appointment is a clear signal to the market. Schade brings a proven ability to guide a company's corporate strategy, build immense value, and execute a successful endgame, whether that be a strategic partnership, a public offering, or an acquisition. For a company like RQ Bio, which is sitting on potentially disruptive technology, having a leader with Schade's transactional acumen and industry-wide credibility is a powerful strategic asset. He will be instrumental in navigating the corporate landscape as the science progresses through the clinic.

A Platform Against Viral Threats

While RQB01 and influenza are the immediate focus, the $115 million investment is also a bet on RQ Bio's underlying antibody discovery platform. The company is not a one-trick pony. Its capabilities were previously validated in the crucible of the COVID-19 pandemic.

RQ Bio's scientists discovered AZD3152, a potent monoclonal antibody for COVID-19 prevention, which was licensed to AstraZeneca and entered clinical trials less than a year after its discovery. This track record demonstrates an ability to rapidly identify and advance powerful antibody candidates against emerging viral threats. The company's vision extends to a pipeline of therapies targeting other respiratory viruses, positioning it as a key player in building a more resilient infrastructure against infectious diseases.

The road ahead for RQ Bio is challenging. The history of medicine is littered with promising influenza antibody therapies that failed in late-stage trials. The regulatory pathway for biologics is arduous and expensive. However, with a validated platform, a massive infusion of strategic capital, and proven leadership at the helm, RQ Bio is now exceptionally well-equipped to take on that challenge and potentially redefine prevention for a disease that has plagued humanity for centuries.